Fidelis Capital Partners’s AstraZeneca AZN Stock Holding History

Fidelis Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$447K	Sell	2,268 -231	-9%	-$44.5K	0.03%	340
2025 Q4	$459K	Buy	2,499 +533	+27%	+$93.5K	0.03%	327
2025 Q3	$302K	Buy	1,966 +139	+8%	+$21K	0.02%	389
2025 Q2	$269K	Sell	1,827 -4	-0.2%	-$561	0.02%	370
2025 Q1	$255K	Buy	1,831 +373	+26%	+$54K	0.03%	352
2024 Q4	$204K	Sell	1,458 -7,288	-83%	-$1.02M	0.02%	420
2024 Q3	$1.35M	Buy	8,746 +739	+9%	+$119K	0.16%	118
2024 Q2	$1.29M	Buy	8,007 +2,466	+45%	+$371K	0.18%	96
2024 Q1	$751K	Buy	5,541 +2,873	+108%	+$380K	0.11%	165
2023 Q4	$359K	Buy	2,668 +469	+21%	+$61K	0.08%	216
2023 Q3	$298K	Buy	2,199 +484	+28%	+$66.1K	0.1%	197
2023 Q2	$245K	Buy	1,715 +367	+27%	+$54K	0.09%	234
2023 Q1	$203K	Buy	+1,348	New	+$181K	0.09%	236

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Fidelis Capital Partners's AZN Position: Q1 2026 in Review

Fidelis Capital Partners reduced its AstraZeneca (AZN) stake by 9.2% in Q1 2026, selling an estimated $44.5K and leaving 2,268 shares worth $447K. The position accounts for 0.03% of the portfolio, ranked #340.

Fidelis Capital Partners first reported a position in AZN in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.35M in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Fidelis Capital Partners held 2,268 shares of AstraZeneca worth $447K as of Q1 2026.
Fidelis Capital Partners sold 231 AstraZeneca shares in Q1 2026, an estimated $44.5K.
AstraZeneca made up 0.03% of Fidelis Capital Partners's portfolio in Q1 2026, its #340 holding.
Fidelis Capital Partners first reported a position in AstraZeneca in Q1 2023 and has held it in 13 quarters since.
Fidelis Capital Partners's AstraZeneca position peaked at $1.35M in Q3 2024.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.